Moderna, Inc. (NASDAQ:MRNA) Shares Bought by Bellevue Group AG

Bellevue Group AG lifted its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 2.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,600,836 shares of the company’s stock after purchasing an additional 37,101 shares during the period. Moderna accounts for about 1.7% of Bellevue Group AG’s portfolio, making the stock its 15th largest holding. Bellevue Group AG owned approximately 0.42% of Moderna worth $106,984,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Commerzbank Aktiengesellschaft FI grew its stake in shares of Moderna by 1.7% during the second quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock worth $660,000 after purchasing an additional 93 shares in the last quarter. CVA Family Office LLC boosted its position in shares of Moderna by 21.6% during the 2nd quarter. CVA Family Office LLC now owns 541 shares of the company’s stock worth $64,000 after acquiring an additional 96 shares in the last quarter. Claro Advisors LLC increased its holdings in shares of Moderna by 2.0% in the 2nd quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock valued at $659,000 after acquiring an additional 108 shares during the last quarter. McAdam LLC raised its position in shares of Moderna by 1.1% during the 2nd quarter. McAdam LLC now owns 11,075 shares of the company’s stock worth $1,315,000 after acquiring an additional 117 shares in the last quarter. Finally, 180 Wealth Advisors LLC lifted its stake in Moderna by 1.1% during the second quarter. 180 Wealth Advisors LLC now owns 14,868 shares of the company’s stock worth $1,826,000 after purchasing an additional 160 shares during the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have commented on MRNA. JPMorgan Chase & Co. dropped their price target on shares of Moderna from $59.00 to $45.00 and set an “underweight” rating on the stock in a research note on Tuesday, November 26th. Oppenheimer cut shares of Moderna from an “outperform” rating to a “market perform” rating in a research report on Friday, September 13th. Barclays decreased their price objective on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. UBS Group cut their target price on Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Finally, TD Cowen decreased their target price on Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a research report on Friday, September 13th. Three analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $83.33.

Insider Activity at Moderna

In other news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. This trade represents a 7.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 1,147 shares of company stock worth $76,245 over the last 90 days. Company insiders own 15.70% of the company’s stock.

Moderna Stock Performance

Shares of MRNA opened at $43.06 on Friday. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The stock’s 50 day moving average is $52.38 and its two-hundred day moving average is $91.10. Moderna, Inc. has a twelve month low of $35.80 and a twelve month high of $170.47.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same period in the previous year, the business earned ($1.39) earnings per share. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. On average, equities analysts expect that Moderna, Inc. will post -9.44 EPS for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.